Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Physiologically-based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population.

CPT: pharmacometrics & systems pharmacology - 1 Aug 2024

Thompson Elizabeth J, Jeong Angela, Helfer Victória E, Shakhnovich Valentina, Edginton Andrea, Balevic Stephen J, James Laura P, Collier David N, Anand Ravinder, Gonzalez Daniel

Abstract excerpt

Pantoprazole is a proton pump inhibitor indicated for the treatment of gastroesophageal reflux disease, a condition that disproportionately affects children with obesity. Appropriately dosing pantoprazole in children with obesity requires understanding the body size metric that best guides dosing, but pharmacokinetic (PK) trials using traditional techniques are limited by the need for larger sample sizes and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to Cytochrome P-450 CYP2C19

Share to Genetic Variation

Share to Models, Biological

Share to Pediatric Obesity

Share to Proton Pump Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 38837864
DOI: 10.1002/psp4.13167
PMCID: PMC11330186

Genes

CYP2C19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Physiologically-based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population.PMID 38837864Read ↗

Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures.Semantic proximity Read ↗

Exploring the Influence of Obesity and CYP2 C19 Genotype on Lansoprazole Pharmacokinetics in Pediatric Patients: A Population Modeling Approach.Semantic proximity Read ↗

PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes.Semantic proximity Read ↗

Population pharmacokinetics of omeprazole in obese and normal-weight adults.Semantic proximity Read ↗

PBPK Modeling of Esomeprazole to Support Adolescent Pharmacokinetic Extrapolation and Label Extension in Chinese Patients With Gastroesophageal Reflux Disease (GERD).Semantic proximity Read ↗

Application of Virtual Twin PBPK Models in Individuals with Obesity via CYP3A4 Phenotyping Using Endogenous Biomarker Data.Semantic proximity Read ↗

Utility of the 13 C-pantoprazole breath test as a CYP2C19 phenotyping probe for children.Semantic proximity Read ↗

A Physiologically Based Pharmacokinetic Framework for Prediction of Drug Exposure in Malnourished ChildrenSemantic proximity Read ↗

Antimicrobial Dosing in Specific Populations and Novel Clinical Methodologies: Obesity.Semantic proximity Read ↗

CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation.Semantic proximity Read ↗

Prediction of Omeprazole Pharmacokinetics and its Inhibition on Gastric Acid Secretion in Humans Using Physiologically Based Pharmacokinetic-Pharmacodynamic Model Characterizing CYP2C19 Polymorphisms.Semantic proximity Read ↗

Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.